{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Computerized+Tomography+scan&page=22", "query": { "intervention": "Computerized Tomography scan", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 2066, "total_pages": 207, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Computerized+Tomography+scan&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Computerized+Tomography+scan&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T05:18:11.819Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05994014", "title": "PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Coronary Artery Disease", "Atherosclerosis", "Coronary Atherosclerosis of Native Coronary Artery" ], "interventions": [ { "name": "PET/CT", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2023-07-01", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-10-21T05:18:11.819Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05994014" }, { "nct_id": "NCT05372614", "title": "Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Solid Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Malignant Solid Neoplasm", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Neratinib Maleate", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2022-10-05", "completion_date": "2028-07-17", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-21T05:18:11.819Z", "location_count": 18, "location_summary": "Duarte, California • Irvine, California • Lancaster, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05372614" }, { "nct_id": "NCT00019604", "title": "Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Cancer", "Metastatic Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "computed tomography", "type": "PROCEDURE" }, { "name": "magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "radiofrequency ablation", "type": "PROCEDURE" }, { "name": "radionuclide imaging", "type": "PROCEDURE" }, { "name": "ultrasound imaging", "type": "PROCEDURE" }, { "name": "fludeoxyglucose F 18 (FDG-PET)", "type": "RADIATION" }, { "name": "gadopentetate dimeglumine", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "1998-08", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2017-02-03", "last_synced_at": "2026-10-21T05:18:11.819Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019604" }, { "nct_id": "NCT03387514", "title": "Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "PSMA-based 18F-DCFPyL PET tracer for PET/CT exams", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2018-12-08", "completion_date": "2021-06-29", "has_results": true, "last_update_posted_date": "2022-12-21", "last_synced_at": "2026-10-21T05:18:11.819Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03387514" }, { "nct_id": "NCT03959085", "title": "Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "B Lymphoblastic Lymphoma", "Central Nervous System Leukemia", "Mixed Phenotype Acute Leukemia", "Testicular Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "365 Days", "maximum_age": "25 Years", "sex": "ALL", "summary": "365 Days to 25 Years" }, "enrollment_count": 5951, "start_date": "2019-10-31", "completion_date": "2032-03-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-21T05:18:11.819Z", "location_count": 203, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03959085" }, { "nct_id": "NCT02286843", "title": "Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer Metastases", "HER2 Positive Breast" ], "interventions": [ { "name": "89Zr-trastuzumab", "type": "RADIATION" }, { "name": "PET/CT scan", "type": "DEVICE" }, { "name": "89Zr-pertuzumab", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "DEVICE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 49, "start_date": "2014-11-06", "completion_date": "2020-06-30", "has_results": true, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-10-21T05:18:11.819Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02286843" }, { "nct_id": "NCT03001349", "title": "68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Meningioma", "Metastatic Well Differentiated Neuroendocrine Neoplasm", "Multiple Endocrine Neoplasia Type 1", "Neuroendocrine Neoplasm", "Somatostatin Positive Neoplastic Cells Present", "Von Hippel-Lindau Syndrome" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68-Edotreotide", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 4, "start_date": "2017-05-16", "completion_date": "2021-02-05", "has_results": false, "last_update_posted_date": "2021-02-15", "last_synced_at": "2026-10-21T05:18:11.819Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03001349" }, { "nct_id": "NCT07600801", "title": "LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol B", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Family History of Lung Cancer" ], "interventions": [ { "name": "CT scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Sybil", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2250, "start_date": "2026-06-17", "completion_date": "2035-12-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-21T05:18:11.819Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07600801" }, { "nct_id": "NCT07455201", "title": "Evaluating a Prototype CT Scan for ICH Evacuation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Intracerebral Hemorrhage" ], "interventions": [ { "name": "DynaCT Multiphase", "type": "DEVICE" }, { "name": "DynaCT Sine Spin", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2025-10-31", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-21T05:18:11.819Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07455201" }, { "nct_id": "NCT06056895", "title": "Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Merkel Cell Carcinoma AJCC v8", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" }, { "name": "Tuparstobart", "type": "DRUG" }, { "name": "Verzistobart", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2023-11-08", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-21T05:18:11.819Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06056895" } ] }